NEW YORK (GenomeWeb News) – Sequenom today released preliminary financial results for the fourth quarter and full-year 2014, projecting $37 million in fourth-quarter revenue and $151 million in annual revenue.

The revenue projection falls short of analyst estimates of $45 million for the quarter and $161 million for the year.

Sequenom disclosed the preliminary financial results on its website ahead of its presentation at the JP Morgan Healthcare Conference later this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.